A lower target of <130 mm Hg or treatment when the baseline SBP was <140 mm Hg was not, however, associated with statistically significantly improved cardiovascular outcomes or mortality. This led to conclusions that achieving an SBP in the range of 130-140 mm Hg is associated with reduced cardiovascular events. There was some evidence for a reduced risk of stroke when patients were treated with antihypertensive therapy when the baseline SBP was <140 mm Hg, though benefits on other cardiovascular outcomes were not seen. Furthermore, there was a non-significant trend towards increased cardiovascular mortality in this group.[59] The SR performed by Ettehad el al. (2016) [54] focused on the general population with HTN but did have a subgroup analysis for patients with diabetes, which provided evidence for the recommendation suggesting treating to the lower target SBP of <130 mm Hg for patients with type 2 diabetes. This is in contrast to the SR by Brunstr m et al. (2017) [59] which provides strong evidence for the older population with type 2 diabetes, including patients with a history of CVD, for a target SBP of 130- 140 mm Hg. The 2014 VA/DoD HTN CPG recommended treatment to an SBP of <150 mm Hg in patients 60 years and over with type 2 diabetes, primarily based on the results of general HTN studies which had sub- populations with diabetes [64,65] and the HTN arm of the UK Prospective Diabetes Study Group.